OncoCyte Corp Valuation
| OCX Stock | USD 3.50 0.12 3.31% |
At this time, the company appears to be overvalued. OncoCyte Corp holds a recent Real Value of $2.81 per share. The prevailing price of the company is $3.5. Our model determines the value of OncoCyte Corp from analyzing the company fundamentals such as Return On Equity of -1.65, current valuation of 104.16 M, and Shares Owned By Insiders of 22.27 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting OncoCyte Corp's valuation include:
Price Book 10.661 | Enterprise Value | Enterprise Value Ebitda (1.25) | Price Sales 146.0218 | Enterprise Value Revenue 146.9075 |
Overvalued
Today
Please note that OncoCyte Corp's price fluctuation is very risky at this time. Calculation of the real value of OncoCyte Corp is based on 3 months time horizon. Increasing OncoCyte Corp's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since OncoCyte Corp is currently traded on the exchange, buyers and sellers on that exchange determine the market value of OncoCyte Stock. However, OncoCyte Corp's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.5 | Real 2.81 | Target 4.13 | Hype 3.62 | Naive 3.57 |
The intrinsic value of OncoCyte Corp's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence OncoCyte Corp's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of OncoCyte Corp helps investors to forecast how OncoCyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of OncoCyte Corp more accurately as focusing exclusively on OncoCyte Corp's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use OncoCyte Corp's intrinsic value based on its ongoing forecasts of OncoCyte Corp's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against OncoCyte Corp's closest peers.
OncoCyte Corp Cash |
|
OncoCyte Valuation Trend
Analysing the historical paterns of OncoCyte Corp's enterprise value and its market capitalization is a good way to estimate and gauge the value of OncoCyte Corp over time and is usually enough for investors to make rational market timing decisions.
OncoCyte Valuation Data Drivers
OncoCyte Corp Total Value Analysis
OncoCyte Corp is now forecasted to have company total value of 104.16 M with market capitalization of 103.53 M, debt of 2.87 M, and cash on hands of 45.41 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the OncoCyte Corp fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
104.16 M | 103.53 M | 2.87 M | 45.41 M |
OncoCyte Corp Investor Information
About 22.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 4.44. OncoCyte Corp had not issued any dividends in recent years. The entity had 1:20 split on the 25th of July 2023. Based on the analysis of OncoCyte Corp's profitability, liquidity, and operating efficiency, OncoCyte Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.OncoCyte Corp Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. OncoCyte Corp has an asset utilization ratio of 2.01 percent. This suggests that the Company is making $0.0201 for each dollar of assets. An increasing asset utilization means that OncoCyte Corp is more efficient with each dollar of assets it utilizes for everyday operations.OncoCyte Corp Ownership Allocation
OncoCyte Corp owns a total of 28.6 Million outstanding shares. Over half of OncoCyte Corp's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.OncoCyte Corp Profitability Analysis
The company reported the last year's revenue of 1.5 M. Reported Net Loss for the year was (27.78 M) with profit before taxes, overhead, and interest of 116 K.About OncoCyte Corp Valuation
Our relative valuation model uses a comparative analysis of OncoCyte Corp. We calculate exposure to OncoCyte Corp's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of OncoCyte Corp's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 474.9 K | 498.7 K | |
| Pretax Profit Margin | (14.88) | (15.63) | |
| Operating Profit Margin | (15.05) | (15.80) | |
| Net Loss | (21.26) | (22.32) | |
| Gross Profit Margin | 0.25 | 0.26 |
OncoCyte Corp Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 7.7 M |
OncoCyte Corp Current Valuation Indicators
Valuation refers to the process of determining the present value of OncoCyte Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value OncoCyte we look at many different elements of the entity such as OncoCyte's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as OncoCyte Corp, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use OncoCyte Corp's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes OncoCyte Corp's worth.Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.